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Duplications in 16p11.2 are a risk factor for schizophrenia
(SCZ). Using genetically modified zebrafish, Golzio and
colleagues identified KCTD13 within 16p11.2 as a major
driver of the neuropsychiatric phenotype observed in
humans. The aims of the present study were to explore the
role of KCTD13 in the development of SCZ and to provide a
more complete picture of the allelic architecture at this risk
locus. The exons of KCTD13 were sequenced in 576
patients. The mutations c.6G>T and c.598G>A were
identified in one patient each. Both mutations were
predicted to be functionally relevant and were absent from
the 1000 Genomes Project data and the Exome Variant
Server. The mutation c.6G>T was predicted to abolish a
potential transcription factor-binding site for specifity
protein 1. Altered specifity protein 1 expression has been
reported in SCZ patients compared with controls. Further
studies in large cohorts are warranted to determine the
relevance of the two identified mutations. Psychiatr Genet
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Introduction
Schizophrenia (SCZ) is a common and often severely dis-
abling neuropsychiatric disorder. Patients show a variety of
symptoms, including hallucinations, delusions, disorganized
speech, affective flattening, and avolition (American
Psychiatric Association, 1994). The estimated heritability of
SCZ ranges between 60 and 80% (Sullivan et al., 2003; Wray
and Gottesman, 2012). Previous research has implicated a
small number of rare copy number variants (CNVs) from
specific chromosomal regions in the risk of SCZ (Malhotra
and Sebat, 2012; Sullivan et al., 2012; Rees et al., 2014).
One of these chromosomal regions is 16p11.2. Duplications
and deletions in 16p11.2 are particularly interesting as they
are implicated in mirrored phenotypes. Deletions in this
region are associated with macrocephaly and obesity
(Bochukova et al., 2010; Shinawi et al., 2010; Walters et al.,
2010; Jacquemont et al., 2011), whereas duplications in
16p11.2 are associated with microcephaly and low BMI
(Shinawi et al., 2010; Jacquemont et al., 2011). Furthermore,
deletions and duplications in this chromosomal region are
established risk factors for developmental delay, intellectual
disability, autism spectrum disorder, and epilepsy (Kumar
et al., 2008; Weiss et al., 2008; Shinawi et al., 2010; Xiang
et al., 2010; Sullivan et al., 2012). However, only duplications
in 16p11.2 increase the susceptibility to SCZ (odds ratio
∼10; McCarthy et al., 2009; Kirov et al., 2012; Sullivan et al.,
2012; Rees et al., 2014; Szatkiewicz et al., 2014).
The CNVs reported to date in 16p11.2 are flanked by
segmental duplications and are typically ∼ 600 kb in size,
spanning more than 25 genes (Weiss et al., 2008). Several
of these are interesting candidate genes for neu-
ropsychiatric phenotypes. Golzio et al. (2012) published
the results of an analysis in genetically modified zebrafish.
The authors generated evidence that KCTD13 is a major
driver of the mirrored neuroanatomical phenotypes of the
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CNVs in 16p11.2 (Malhotra and Sebat, 2012). In zebra-
fish, overexpression of the KCTD13 human transcript
caused microcephaly, which resembled the microcephaly
phenotype associated with the 16p11.2 duplication. In
contrast, inhibition of KCTD13 expression caused a mac-
rocephalic phenotype, which has been associated pre-
viously with the 16p11.2 deletion (Golzio et al., 2012;
Malhotra and Sebat, 2012). In addition, KCTD13 is located
in one of the 108 genome-wide significant loci reported in
the largest SCZ genome-wide association study world-
wide (36 989 patients and 113 075 controls; Schizophrenia
Working Group of the Psychiatric Genomics Consortium,
2014).
The aims of the present study were to explore the role of
KCTD13 in the development of SCZ and to provide a
more complete picture of the allelic architecture at the
16p11.2 risk locus. The identification of rarer variants in
this gene might provide genetic evidence for the role of
KCTD13 in susceptibility to SCZ. Furthermore, rarer
variants with higher penetrance might be more suitable
for functional follow-up studies than common variants
with small effects.
Methods
The study was approved by the respective ethics commit-
tees and all participants provided written informed consent
before inclusion. All study procedures were carried out in
accordance with the Code of Ethics of the World Medical
Association (Declaration of Helsinki). All participants were
of German descent according to self-reported ancestry.
Sample description
In total, 576 patients were included. The patients were
recruited from consecutive admissions to psychiatric inpa-
tient units in Germany. A lifetime ‘best estimate’ diagnosis
(Leckman et al., 1982) of SCZ according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th ed., criteria
(American Psychiatric Association, 1994) was assigned on
the basis of the medical records, family history, and the
Structured Clinical Interview (Spitzer et al., 1992) and/or
the OPCRIT (McGuffin et al., 1991). Each individual was
of German descent according to self-reported ancestry.
Sanger sequencing
Primer design was based on the NCBI37/hg19 reference
sequence (Ensembl transcript ID: ENST00000568000).
All six coding exons and their flanking sequences (± 30 bp
of each exon analyzed) were amplified. Exons 3 and 4
were grouped together in one amplicon. Sanger sequen-
cing was performed in part at Beckman Coulter Genomics
(Takeley, UK) and in part at the Institute of Human
Genetics in Bonn. The variants identified were confirmed
at the Institute of Human Genetics in Bonn by sequen-
cing the complementary strand of a second, independent
amplicon. For the verification step, the 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, California,
USA) was used. The nucleotide sequences obtained were
analyzed using SeqMan II (DNASTAR, Madison,
Wisconsin, USA). Primer sequences are obtainable upon
request.
Analysis of sequence variants
To predict the effect of an amino-acid change on protein
function, scores from the following three programs were
used: MutationTaster (Schwarz et al., 2010; http://muta
tiontaster.org/); PolyPhen-2, version 2.2.2 (Adzhubei et al.,
2010; http://genetics.bwh.harvard.edu/pph2/); and SIFT (Ng
and Henikoff, 2001; http://sift.jcvi.org/). To obtain informa-
tion on transcription-binding sites that might be altered by
the identified mutations, a search was performed of the
TRANSFAC public database (Wingender et al., 1996;
http://www.gene-regulation.com/pub/databases.html).
To maximize the number of patients included in the
sequencing step, no controls were sequenced and pub-
lically available datasets were used to calculate the allele
frequency of the identified variants. The allele frequency
of the identified variants was checked in the 1000
Genomes Project data (Abecasis et al., 2010; Total
European Ancestry EUR; http://www.1000genomes.org/),
and the Exome Variant Server (European American
population; Exome Variant Server, NHLBI GO Exome
Sequencing Project, Seattle, Washington, USA (http://evs.
gs.washington.edu/EVS/) (November 2015).
Results
High-quality sequencing data were obtained from (i) 552
patients for exon 1; (ii) 554 patients for exon 2; (iii) 563
patients for exons 3, 4, and 5; and (iv) 571 patients for
exon 6. Two variants were identified and verified in one
patient each: (i) c.6G>T in exon 1 and (ii) c.598G>A in
exon 5. These variants were present in neither the 1000
Genomes Project data nor the Exome Variant Server. No
additional variants were identified in our sample.
The mutation c.6G>T in exon 1 is a synonymous substitu-
tion, which was in-silico predicted to be disease causing
(MutationTaster). According to TRANSFAC (Wingender
et al., 1996), the alteration in the DNA sequence abolishes a
potential transcription factor-binding site for Sp1. The non-
synonymous substitution c.598G>A in exon 5 p.Asp200Asn
was predicted to be functionally relevant by Polyphen-2
(probably damaging); SIFT (damaging); and MutationTaster
(disease causing).
No parental DNA was available to test whether the
mutation c.6G>T in exon 1 was inherited or de novo. The
mutation c.598G>A in exon 5 had not been inherited from
the respective patient’s mother. However, the patient’s
brother was shown to carry the same mutation. No paternal
DNA was available for testing. The brother of the patient
was diagnosed with recurrent major depression, agor-
aphobia, and an unspecified eating disorder. No informa-
tion on the head size of the mutation carriers was available.
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Discussion
The synonymous mutation c.6G>T was in-silico predicted
to abolish a potential transcription factor-binding site for
specifity protein 1 (SP1). The zinc finger transcription
factor SP1 is located on chromosome 12q13.13 and reg-
ulates the expression of a number of genes by binding to
GC-rich sequences (Suske, 1999). Several studies have
reported altered SP1 expressions in patients with SCZ
compared with controls (Ben-Shachar and Karry, 2007;
Fusté et al., 2013; Pinacho et al., 2013, 2014). In a small
sample of first-episode psychosis patients, Fusté et al.
(2013) found reduced SP1 protein levels in mononuclear
cells from peripheral blood (Fusté et al., 2013).
Ben-Shachar and Karry (2007) carried out postmortem
expression analyses in various human brain regions. The
authors identified significantly decreased SP1 messenger
RNA levels in the prefrontal cortex and in the striatum,
with increased levels in the ventral parieto-occipital cortex
and in lymphocytes (Ben-Shachar and Karry, 2007).
Pinacho et al. (2014) reported significantly increased SP1
messenger RNA expression levels in the postmortem
hippocampus of patients with chronic SCZ (Pinacho et al.,
2014).
The mutation c.6G>T is not reported in either the 1000
Genomes Project data or the Exome Variant Server (total of
∼4.700 individuals). In the European (non-Finnish) sample
ascertained by the Exome Aggregation Consortium (ExAC)
(Cambridge, Massachusetts, USA) (http://exac.broadinstitute.
org), the c.6G>T mutation was detected in 43 of 7838
European individuals (allele frequency=0.003). Notably,
ExAC includes data from the 1000 Genomes Project, the
Exome Variant Server [NHLBI GO Exome Sequencing
Project, and sequencing studies in patients with psychiatric
disorders. The mutation was not detected in the
Schizophrenia Exome Sequencing Genebook (Purcell et al.,
2014; http://atgu.mgh.harvard.edu/∼ spurcell/genebook/genebook.cgi?
user= guest&cmd= search-gene&tbox=KCTD13)], which con-
tains the exome sequencing data of 2536 SCZ patients and
2543 controls.
The nonsynonymous substitution c.598G>A in exon 5
(p.Asp200Asn) is not reported in the 1000 Genomes Project
data or the Exome Variant Server. In the European (non-
Finnish) ExAC sample, the mutation c.598G>A was identi-
fied in 3 of 33 154 individuals (allele frequency=0.00005). In
the Swedish SCZ exome-sequencing study, this mutation
was identified in one patient and in one control (Purcell et al.,
2014; http://atgu.mgh.harvard.edu/∼ spurcell/genebook/genebook.cgi?
user= guest&cmd= search-gene&tbox=KCTD13). At the protein
level, the G>A substitution causes an exchange of the
charged acidic amino-acid aspartic acid to the polar uncharged
amino acid asparagine. Moreover, Asp200 is strictly conserved
at its corresponding position in KCTD13 as far down as Danio
rerio (data from Swiss-Prot).
To date, exome sequencing data from eight studies ana-
lyzing de-novo mutations in more than 850 patients with
SCZ have been published (Girard et al., 2011; Xu et al., 2011,
2012; Gulsuner et al., 2013; Fromer et al., 2014; Guipponi
et al., 2014; McCarthy et al., 2014; Kranz et al., 2015). None of
these studies reported a mutation in KCTD13.
The present study has three main limitations. First, the
sequencing of KCTD13 was restricted only to patients.
During the project design phase, we opted to sequence
KCTD13 in as many patients as possible, rather than
reducing the number of patients to cover the cost of
sequencing controls. Second, we could not determine the
phenotype of the mutation carriers identified in ExAC.
This hampers the interpretation of the allele frequency
reported for the two mutations identified in the present
analyses. In particular, information on the variant carriers’
head size and their mental wellbeing would have
improved the data interpretation. Third, we focused our
analysis on exonic variants and therefore cannot rule out
the presence of phenotypically relevant mutations in
regulatory regions. Furthermore, KCTD13 is an interest-
ing candidate gene on the basis of a study in genetically
modified zebrafish (Golzio et al., 2012). Therefore, we
cannot rule out that genetic variants in a/several other
genes located in 16p11.2 contribute toward the neu-
ropsychiatric phenotype observed among human CNV
carriers. Future studies sequencing all genes located in
16p11.2 are warranted to obtain more information on
their relevance to disease pathogenesis.
The lack of an association between single base pair muta-
tions in KCTD13 and SCZ, both in the present study and in
the previously published exome sequencing data, may
indicate that rare point mutations in this gene do not con-
tribute toward the genetic architecture of SCZ, or alter-
natively, that mutations in this gene are extremely rare. Our
study generated no strong evidence for the involvement of
damaging mutations in KCTD13 in the development of
SCZ. Therefore, the relevance of the identified rare
mutations in KCTD13 remains unclear. Further studies in
large, independent cohorts are now warranted.
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